by Minomic | Feb 14, 2019
Agreement enables early access to the MiCheck® Prostate Cancer Test for US Clinicians & Patients February 14, 2019: [Sydney] Minomic International Ltd is pleased to announce the company has executed an agreement with Cirrus Dx, a CLIA Certified “High Complexity”...
by Minomic | Sep 14, 2018
Dr Brad Walsh awarded first prize to boost Minomic’s efforts for MiCheck® China launch – offering a better solution for prostate cancer diagnosis 13 September 2018: [Sydney] Diagnostic company Minomic International Ltd today announced it had secured first prize...
by Minomic | May 17, 2018
58% Fewer patients proceed to Biopsy. US Rollout well advanced. May 17, 2018: [Sydney] Australian immuno-oncology company Minomic International Ltd is pleased to announce the completion of its prospective clinical trial of the company’s novel prostate cancer...
by Minomic | Feb 14, 2018
Facebook Twitter Google+ LinkedIn A poster with headline results of the MiCheck-01 prospective trial was presented by Dr Brad Walsh, Minomic’s CEO at ASCO GU Cancers Symposium 2018 on 8 February. The 350-patient study highlights the test’s performance in...
by Minomic | Jul 19, 2017
Facebook Twitter Google+ LinkedIn Novel prostate cancer screening technology targeting commercialization in 2017 Verification of test accuracy and reliability for CLIA lab access July 18, 2017: [Sydney] Minomic International Ltd, an Australian immuno-oncology company,...
